Interested working with us
WHY CHOOSE KEXING
Kexing Biopharm is an innovative biopharmaceutical enterprise mainly engaged in the R&D, production and sales of recombinant protein drugs and microecological preparations. Focusing on antiviral therapy and the treatment of tumor, autoimmune, metabolic diseases, degenerative diseases and other therapeutic fields , it is dedicated to building cutting-edge biotechnology platforms for new protein, new antibody, nucleic acid and other drugs. Adhering to the platform driven development model of "innovation+internationalization", It also explores the extensive application of biotechnology in the big health sector. It is committed to becoming a leader in high-quality biological drugs and serving global patients.
Kexing Biopharm offers a diversified portfolio of 22 innovative products, including drugs "Human Erythropoietin Injection (EPOSINO)", "Human Interferon α1b for Injection (SINOGEN)" and "Human Granulocyte Colony-stimulating Factor Injection (WHITE-C)"; microecological agents, notably "Combined Clostridium Butyricum and Bifidobacterium Powder/Capsule, Live (CLOBICO)"; targeted drugs, such as "Albumin-bound Paclitaxel (Apexelsin)" and "Infliximab for Injection (Reminton)". Our core products outperform competitors' options in China, with SINOGEN and EPOSINO leading positions in their respective therapeutic categories, consistently securing the top two rankings in market share. Our products are supplied to over 20,000 sales terminals across China, including over 8,000 hospitals, 7,700 third-party terminals, and over 3,000 pharmacies. In addition, we have established 6 overseas subsidiaries, which have acquired market access and achieved sales in over 70 countries and regions such as the European Union, Brazil, Philippines and Indonesia. In recent years, we also have created a high-quality biopharmaceuticals overseas platform based on the concept of "Global Product Selection + Global Product Coverage", and secured commercial partnerships with numerous renowned pharmaceutical companies worldwide by leveraging its global marketing infrastructure, targeted market penetration strategies, and commitment to delivering premium-quality products and services.
Kexing Biopharm operates multiple R&D centers, such as the Shenzhen Medical Research Institute, the Shandong R&D Center and the Guangzhou R&D Center. It boasts an R&D team of nearly 200 members, with over 60% holding master's degrees or higher. At present, it has obtained 65 patents. The Company has established a complete drug R&D and innovation system with three major biotechnology systems: Prokaryotic cell technology, eukaryotic cell technology, and viable bacteria technology. Depending on these systems, it has built several leading technology platforms worldwide, such as KX-FUSION Fusion Protein Technology Platform, KX-BODY Antibody Technology Platform, K'Exosome Delivery Technology Platform, Vector Vaccine Technology Platform, and Microecological Agent R&D and Industrialization Technology Platform.
The Company focuses on biopharmaceuticals and implements a strategic R&D plan that enables a tiered, serial, and graduated product portfolio. Our short-term efforts are concentrated on in-depth development around new formulations, new indications and long-acting effects for recombinant protein therapeutics. In the medium and long term, we focus on fields such as oncology, immunology and degenerative diseases, with plans to develop new antibodies, proteins and nucleic acid drugs. It boasts robust pipelines of innovative drugs and dozens of projects currently under development, including GB05 Human Interferon α1b Inhalation Solution (Phase III clinical trial), GB-K02 Long-acting Human Granulocyte Colony-stimulating Factor Injection (Phase III clinical trial), GB08 Long-acting Growth Hormone (completed Phase I clinical trial), GB10 (target: VEGF/ANG-2) for fundus diseases, GB12 (target: IL-4/IL-31) for atopic dermatitis, GB18 (target: GDF-15) for cancer cachexia, GB23 (target: IFN/GPC3/PD1) for solid tumors, GB24 (target: TL1A, bispecific antibody) for inflammatory bowel diseases, and GB25 (tri-specific antibody) for colorectal cancer.
Following the mission of "Precise Products, Predictable Effects, Health Protection", we are devoted to providing patients with biotechnology and becoming the leader in high-quality biologics!
